{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T01:27:22Z","timestamp":1699925242185},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T00:00:00Z","timestamp":1245196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p>Oral fludarabine is more convenient than intravenous fludarabine in an outpatient setting. To assess the efficacy and toxicity of oral fludarabine in combination with rituximab in patients with relapsed indolent B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL), we conducted a multicenter phase II study. Patients with relapsed indolent B\u2010NHL with two or fewer prior regimens and up to 16 doses of rituximab were eligible. Patients received 375\u00a0mg\/m<jats:sup>2<\/jats:sup> rituximab on day 1, and 40\u00a0mg\/m<jats:sup>2<\/jats:sup> oral fludarabine once daily on days 1 through 5 every 28\u00a0days for up to six cycles. The primary endpoint was the overall response rate. Forty\u2010one patients were enrolled, including 38 (93%) with follicular lymphoma. Thirty\u2010four patients (83%) had received rituximab as prior therapy. Twenty\u2010seven patients (66%) completed the planned six cycles. Dose reduction of oral fludarabine was required in 17 patients (41%). The overall response rate was 76% (31 of 41 patients; 95% confidence interval, 60\u201388%) with a complete response rate of 68% (28 of 41 patients; 95% confidence interval, 52\u201382%). Median progression\u2010free survival for the 41 patients was 19.7\u00a0months (95% confidence interval, 12.3\u201326.5 months). Hematological toxicities, including grade 4 neutropenia (68%), were the most frequent toxicities. Non\u2010hematological toxicities were mild, except for one patient who died of <jats:italic>Pneumocystis jiroveci<\/jats:italic> pneumonia 4\u00a0months after the protocol treatment. In conclusion, oral fludarabine in combination with rituximab is a highly effective and convenient therapy for patients with relapsed indolent B\u2010NHL who have mostly been pretreated with rituximab. (ClinicalTrials.gov number, NCT00311129.) (<jats:italic>Cancer Sci<\/jats:italic>\u00a02009; 100: 1951\u20131956)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01247.x","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T07:21:25Z","timestamp":1245223285000},"page":"1951-1956","source":"Crossref","is-referenced-by-count":8,"title":["Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B\u2010cell non\u2010Hodgkin lymphoma"],"prefix":"10.1111","volume":"100","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken\u2010ichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Terauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Nawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Matsusako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,14]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin's lymphomas","volume":"20","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00173.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_7_8_2","doi-asserted-by":"crossref","first-page":"482s","DOI":"10.1200\/jco.2008.26.15_suppl.8616","article-title":"Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R\u2010CHOP) in untreated indolent B\u2010NHL: 7\u2010year follow\u2010up results","volume":"26","author":"Itoh K","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.28"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.790"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.068"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.71"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0269"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.987"},{"key":"e_1_2_7_16_2","first-page":"282a","article-title":"Increased mortality associated with higher dose cyclophosphamide plus fludarabine in advanced stage indolent lymphoma patients treated on E1496, an ECOG and CALGB study","volume":"21","author":"Hochster H","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21151"},{"key":"e_1_2_7_18_2","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down\u2010regulation of bcl\u20102 and sensitization of B\u2010cell non\u2010Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas S","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_19_2","first-page":"2961","article-title":"Potentiation of fludarabine cytotoxicity on non\u2010Hodgkin's lymphoma by pentoxifylline and rituximab","volume":"20","author":"Alas S","year":"2000","journal-title":"Anticancer Res"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03014.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1997.12.177"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.172"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj069"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.9313"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04077"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf155"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl393"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01247.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01247.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:59:58Z","timestamp":1695938398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01247.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,14]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01247.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01247.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,14]]}}}